Multipotent Adult Stem Cells, Sources Thereof, Methods of Obtaining and Maintaining Same, Methods of Differentiation Thereof, Methods of Use Thereof and Cells Derived Thereof

Abstract

Methods and compositions are provided for circularizing target sequences in a sample. In particular, ligation oligonucleotides are employed to selectively hybridize with the target such that the target can be ligated into a closed circular target. Rolling circle amplification can then be performed directly on the target sequence for subsequent detection and analysis.

1 - 101 . (canceled) 
     
     
         102 . A substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor. 
     
     
         103 . The substantially homogenous cell population of  claim 102 , further including co-expression of telomerase. 
     
     
         104 . The substantially homogenous cell population of  claim 102 , wherein the cells are derived from human bone marrow cells. 
     
     
         105 . The substantially homogenous cell population of  claim 102 , wherein the cardiac-related transcription factor is selected from the group consisting of GATA4, Irx4 and NRx2.5. 
     
     
         106 . The substantially homogenous cell population of  claim 102 , further including a label. 
     
     
         107 . The substantially homogenous cell population of  claim 102 , wherein the cell population differentiates into cardiac muscle cells. 
     
     
         108 . The substantially homogenous cell population of  claim 102 , wherein the cells express at least one trophic factor selected from the group consisting of IL-6, VEGF, MCP1 and BDNF. 
     
     
         109 . A substantially homogenous cell population which co-expresses CD49c, CD90, and at least one cardiac-related transcription factor, but does not express bone sialoprotein. 
     
     
         110 . The substantially homogenous cell population of  claim 109 , wherein the cardiac-related transcription factor is selected from the group consisting of GATA4, Irx4 and NRx2.5. 
     
     
         111 . A substantially homogenous cell population which co-expresses CD49c, CD90, GATA4, Irx4 and NRx2.5. 
     
     
         112 . A substantially homogenous cell population which co-expresses CD49c, CD90, telomerase, GATA4, lrx4 and NRx2.5. 
     
     
         113 . A substantially homogenous cell population which co-expresses CD49c, CD90 and has a doubling time of less that about 144 hours when cultured under a low oxygen condition. 
     
     
         114 . The substantially homogenous cell population of  claim 113 , wherein the doubling time is less than about 72 hours. 
     
     
         115 . The substantially homogenous cell population of  claim 113 , wherein the doubling time is less than about 48 hours. 
     
     
         116 . The substantially homogenous cell population of  claim 113 , wherein the doubling time is less than about 65 hours. 
     
     
         117 . The substantially homogenous cell population of  claim 113 , wherein the doubling time is less than about 35 hours. 
     
     
         118 . The substantially homogenous cell population of claim  151 , wherein the low oxygen condition is less than about 5% oxygen. 
     
     
         119 . A substantially homogenous cell population which co-expresses CD49c, CD90 and has a doubling time less than about 144 hours when cultured under a low oxygen condition, wherein the substantially homogenous cell population is formed by a method, comprising the step of culturing a cell population source at a seeding density of about 100 cells/cm.sup.2 under the low oxygen condition. 
     
     
         120 . A pharmaceutical composition comprising a substantially homogenous cell population which co-expresses CD49c, CD90 and at least one cardiac-related transcription factor. 
     
     
         121 . A pharmaceutical composition comprising a substantially homogenous cell population which co-expresses CD49c, CD90, telomerase and at least one cardiac-related transcription factor. 
     
     
         122 . A pharmaceutical composition comprising a substantially homogenous cell population which co-expresses CD49c, CD90, telomerase, GATA4, Irx4 and NRx2.5. 
     
     
         123 . A pharmaceutical composition comprising a substantially homogenous cell population which co-expresses CD49c, CD90, GATA4, Irx4 and NRx2.5.